Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Invested Capital (ROIC) | (212.6%) | (315.4%) | (269.3%) | (659.8%) | (171.1%) | (325.7%) | 46.9% | 29.3% | 204.7% | (596.0%) | (1,188.8%) | (822.9%) | (780.7%) | (350.2%) | (332.0%) | (188.1%) | (107.6%) | (77.5%) | (70.0%) | (18.9%) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Invested Capital (ROIC) is (19.0%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Invested Capital (ROIC) for Alnylam Pharmaceuticals, Inc. have been (56.6%) over the past three years, and (79.5%) over the past five years.
As of today, Alnylam Pharmaceuticals, Inc.'s Return on Invested Capital (ROIC) is (19.0%), which is higher than industry median of (123.1%). It indicates that Alnylam Pharmaceuticals, Inc.'s Return on Invested Capital (ROIC) is Good.